Results 11 to 20 of about 85,963 (263)
Topical JAK inhibitor for refractory skin inflammation in STAT1 GOFTopical JAK inhibitor in STAT1 GOF [PDF]
Journal of Human ImmunityTopical ruxolitinib induced rapid and sustained improvement of refractory skin inflammation in a child with STAT1 GOF disease, highlighting its potential in managing localized inflammation in immune dysregulation.
Valentina Guarnieri +3 more
doaj +2 more sources
Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti‐MDA5 Dermatomyositis–Related Interstitial Lung Disease: A Pilot Study [PDF]
ACR Open RheumatologyObjective To evaluate the clinical characteristics and serum cytokine profiles of patients with anti‐MDA5 antibody–positive dermatomyositis with interstitial lung disease (MDA5+ DM‐ILD) treated with JAK inhibitors and to compare survivors and ...
Haruna Matsuo +11 more
doaj +2 more sources
Pifu-xingbing zhenliaoxue zazhi, 2022 Alopecia areata (AA) is a chronic heterogeneous inflammatory disease, with unknown pathogenesis. Although there are quite a few options to choose for treatment of AA, there is no specific therapic method, and neither is one therapic method for all ...
Xingqi ZHANG
doaj +1 more source
The JAK-STAT Pathway and the JAK Inhibitors [PDF]
Journal of Clinical Research in Dermatology, 2020 Dozens of cytokines that bind Type I and Type II receptors use the Janus Kinases (JAK) and the Signal Transducer and Activator of Transcription (STAT) proteins pathway for intracellular signaling, orchestrating hematopoiesis, inducing inflammation, and controlling the immune response.
Ana Paula Galli Sanchez +2 more
openaire +1 more source
Immunological Medicine, 2023 Recent studies have demonstrated that Janus kinase (JAK) plays a crucial role in signal transduction by directly affecting various cytokine receptors involved in inflammatory diseases such as atopic dermatitis (AD).
Toshiaki Kogame +2 more
doaj +1 more source
JAK inhibitors in autoinflammation [PDF]
Journal of Clinical Investigation, 2018 Interferonopathies are a subset of autoinflammatory disorders with a prominent type I IFN gene signature. Treatment of these patients has been challenging, given the lack of response to common autoinflammatory therapeutics including IL-1 and TNF blockade.
Hal M, Hoffman, Lori, Broderick
openaire +2 more sources
HemaSphere, 2023 The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF).
Jean-Jacques Kiladjian +19 more
doaj +1 more source
JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. [PDF]
PLoS ONE, 2015 Constitutive activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) axis is fundamental to the molecular pathogenesis of a host of hematological disorders, including acute leukemias and myeloproliferative neoplasms ...
Jun Guo +5 more
doaj +1 more source
Methotrexate Is a JAK/STAT Pathway Inhibitor. [PDF]
PLoS ONE, 2015 The JAK/STAT pathway transduces signals from multiple cytokines and controls haematopoiesis, immunity and inflammation. In addition, pathological activation is seen in multiple malignancies including the myeloproliferative neoplasms (MPNs).
Sally Thomas +5 more
doaj +1 more source
Immunological Medicine, 2023 Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons. Indeed, recent rapid progress in JAK inhibitors in addition to biological agents provided therapeutic options for various diseases, including immune-mediated ...
openaire +3 more sources